|本期目录/Table of Contents|

[1]樊茂蓉 苗青 张琼 张燕萍 徐凤芹 樊长征 周伟 柯志成 张旭丽 郑靖铁.通肺络补宗气方提高特发性肺间质纤维化患者活动耐力的临床研究[J].环球中医药,2017,10(03):284-287.[doi:10.3969/j.issn.1674-1749.2017.03.007]
　FAN Maorong,MIAO Qing,ZHANG Qiong,et al.Study of the effect and mechanism of Tongfeiluo Buzongqi prescription on activity endurance of patients with idiopathic pulmonary interstitial fibrosis[J].,2017,10(03):284-287.[doi:10.3969/j.issn.1674-1749.2017.03.007]
点击复制

通肺络补宗气方提高特发性肺间质纤维化患者活动耐力的临床研究()
     
分享到：

《环球中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
第10卷
期数:
2017年03期
页码:
284-287
栏目:
论著
出版日期:
2017-03-06

文章信息/Info

Title:
Study of the effect and mechanism of Tongfeiluo Buzongqi prescription on activity endurance of patients with idiopathic pulmonary interstitial fibrosis
作者:
樊茂蓉 苗青 张琼 张燕萍 徐凤芹 樊长征 周伟 柯志成 张旭丽 郑靖铁
100091 中国中医科学院西苑医院呼吸科
Author(s):
FAN Maorong; MIAO Qing;  ZHANG Qiong;  et al.
Xiyuan Hospital, China Academy of Chinese Medical Science, Beijing 100091, China
关键词:
特发性肺间质纤维化;  通肺络补宗气方;  活动耐力;  临床研究
Keywords:
Idiopathic pulmonary fibrosis;  Tongfeiluo Buzongqi prescription;  Activity endurance;  Clinical study
分类号:
R285.6
DOI:
10.3969/j.issn.1674-1749.2017.03.007
文献标志码:
A
摘要:
目的 观察通肺络补宗气方在提高特发性肺间质纤维化患者活动耐力方面的疗效及安全性。方法 将50例此类患者随机分为两组,观察组25例,对照组25例,对照组采用大剂量N-乙酰半胱氨酸治疗,观察组在此基础上加服通肺络补宗气方,疗程3个月。结果 在6分钟步行距离、圣·乔治呼吸问卷、呼吸困难及咳嗽症状方面,观察组均优于对照组(P＜0.05),肺功能两组之间比较无统计学意义,且两组患者均无严重不良事件出现。结论 通肺络补宗气方能明显提高患者的活动耐力、改善患者生活质量及稳定肺功能,并且能够减轻患者呼吸困难及咳嗽症状。
Abstract:
Objective To investigate the effect of Tongfeiluo Buzongqi prescription on activity endurance of patients with Idiopathic Pulmonary Fibrosis(IPF)and evaluate its safety. Methods 50 patients with IPF were randomly divided into two groups. The control group was treated with large dosage of N-Acetyl-L-cysteine,while the treatment group was treated with Tongfeiluo Buzongqi prescription plus large dosage of N-Acetyl-L-cysteine. The treatment period is three months. Results The treatment group was better efficacy than control group in the 6-minute walk distances,St.George's Respiratory Questionnaire,dyspnoea score and cough score(P＜0.05). There was no statistical significance between the two groups of lung function, and there were no serious adverse events in the two groups. Conclusion Tongleiluo Buzongqi prescription can significantly improve the activity endurance and quality of life of patients,can stabilize lung function and alleviate symptoms of dyspnea and cough.

参考文献/References:

[1] Raghu G,Collard HR,Egan J,et al. An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and anagement[J]. Am J Respir Crit Care Med,2011,183:788-824.
[2] 蔡后荣.2011年特发性肺间质纤维化诊断和治疗循证新指南解读[J]. 中国呼吸与危重监护杂志,2011,10(4):313-316.
[3] Watter LC,King TE,Schw arz MI,et al.A clinical,Radiographic,and Physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis[J].Am Rev Respir Dis,1986,133:97.
[4] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:14-65.
[5] 田德禄. 中医内科学[M]. 北京:人民卫生出版社,2003:368-378.
[6] 张心月,贾新华,王立娟,等.从气血变化看肺间质纤维化[J]. 中医药学报,2012,40(3):56-57.
[7] 樊茂蓉,张燕萍,苗青,等.肺间质纤维化的中医发病机制与治则探讨[J]. 中医杂志,2012,53(3):203-204.
[8] 杨景青,张伟.论叶氏“络病理论”治疗肺间质纤维化[J]. 辽宁中医药大学学报,2013,15(3):118-119.
[9] Jones PW,Quirk FH,Baveystock CM. The St Georg's Respiratory Questionnaire[J]. Respir Med,1991,85(Suppl B):25-31.
[10] American Thoracic Society/European Respiratory Society.American thoracic society/european respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias[J]. Am J Respir Crit Care Med,2002,165(2):277-304.
[11] 中华医学会呼吸病学分会. 特发性肺(间质)纤维化诊断和治疗指南(草案)[J]. 中华结核和呼吸杂志,2002,25(7):387-389.
[12] Raghu G,Weycker D,Edelsberg J,et al. Incidence and prevalence of idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med,2006,174:810-816.
[13] Paul W. Noble,Carlo Albera,Williamson Z,et al. Pirfenidone for idiopathic pulmonary fibrosis:analysis of pooled data from three multinational phase 3 trials[J]. Eur Respir J,2016,47:243-253.
[14] Tamera Cortel,Francesco Bonella,Bruno Crestani,et al. Safety,tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Corte et al[J]. Respiratory Research,2015,16:116-126.
[15] 罗莉莎.槲皮素抗纤维化作用机制研究进展[J]. 国外医学:中医中药分册,2005,27(6):330-332.

相似文献/References:

[1]曹芳,吴志松,付小芳,等.肺痹汤治疗特发性肺间质纤维化咳嗽22例[J].环球中医药,2015,8(01):87.[doi:10.3969/j.issn.1674-1749.2015.01.023]

备注/Memo

备注/Memo:
基金项目: 国家自然科学基金(30901948); 北京市科学技术委员会课题(Z131107002213053); 北京市自然科学基金(7162168)
作者简介: 樊茂蓉(1974- ),女,博士,副主任医师。研究方向:中西医结合呼吸病学。E-mail:fanmr1974@qq.com
通信作者: 徐凤芹(1962- ),女,博士,主任医师。研究方向:中西医结合老年病学、中西医结合心血管病学。E-mail:18800021979@163.com
更新日期/Last Update: 2017-03-06